US 12,146,001 B2
Treatment of allergic diseases with chimeric protein
Bruce Hammerberg, Raleigh, NC (US); Sitka Eguiluz-Hernandez, Raleigh, NC (US); and Thierry Olivry, Raleigh, NC (US)
Assigned to North Carolina State University, Raleigh, NC (US)
Filed by North Carolina State University, Raleigh, NC (US)
Filed on Apr. 1, 2022, as Appl. No. 17/711,517.
Application 17/711,517 is a continuation of application No. 15/934,834, filed on Mar. 23, 2018, granted, now 11,352,443.
Application 15/934,834 is a continuation in part of application No. PCT/US2017/060314, filed on Nov. 7, 2017.
Claims priority of provisional application 62/511,535, filed on May 26, 2017.
Claims priority of provisional application 62/419,788, filed on Nov. 9, 2016.
Prior Publication US 2022/0220223 A1, Jul. 14, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 14/735 (2006.01); C07K 16/42 (2006.01); C07K 19/00 (2006.01); A61K 39/00 (2006.01); A61P 37/08 (2006.01)
CPC C07K 16/4291 (2013.01) [A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07K 14/70535 (2013.01); C07K 19/00 (2013.01); A61K 2039/505 (2013.01); A61P 37/08 (2018.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01); C07K 2319/70 (2013.01)] 20 Claims
 
1. A chimeric protein comprising:
a) a single chain variable fragment (scFv), wherein the scFv comprises:
(i) a light chain (LC) variable region having at the respective complementarity determining regions 1, 2, and 3 (LC-CDR1, LC-CDR2, and LC-CDR3) the amino acid sequences of:
 
 (LC CDR1; SEQ ID NO: 2)
 
 RASGNIHNYL;
 
 
 
 (LC CDR2; SEQ ID NO: 3)
 
 NAKTLAD;
 
 and
 
 
 
 (LC CDR3; SEQ ID NO: 4)
 
 FWSTPYT;
and
(ii) a heavy chain (HC) variable region having at the respective complementarity determining regions 1, 2, and 3 (HC-CDR1, HC-CDR2, and HC-CDR3) the amino acid sequences of:
 
 (HC CDR1; SEQ ID NO: 5)
 
 GYTIH;
 
 
 
 (HC CDR2; SEQ ID NO: 6)
 
 LINPYTGGITYNQNFKGKAT;
 
 and
 
 
 
 (HC CDR3; SEQ ID NO: 7)
 
 GPYGNFYAMDY;
b) a linker peptide comprising 4 amino acids to 200 amino acids; and
c) an amino acid sequence comprising an IgE high affinity receptor alpha chain.